Skip to main content
. Author manuscript; available in PMC: 2021 Nov 10.
Published in final edited form as: J Control Release. 2020 Sep 3;327:788–800. doi: 10.1016/j.jconrel.2020.09.003

Figure 1:

Figure 1:

Overview of CRISPR-Cas technology for medicine. A) Cas nucleases create targeted DSBs in dsDNA via gRNA hybridization with complementary DNA. Shows a molecular graphic of spCas9 with guide RNA in complex with DNA. PDB ID: #4OO8 [24]. Rendered with UCSF ChimeraX [25]. B) Potential therapeutic applications of CRISPR-Cas [26,27].